Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Frequent incidence of BARD1-truncating mutations in germline DNA from triple-negative breast cancer patients.

Clinical genetics - 1 Mar 2016

De Brakeleer S, De Grève J, Desmedt C, Joris S, Sotiriou C, Piccart M, Pauwels I, Teugels E

Abstract excerpt

Triple-negative breast cancer (TNBC) accounts for 10-20% of all breast cancers (BCs), and conventional chemotherapy is the only effective systemic treatment. Germline BRCA1/2 mutations are found in approximately 15% of TNBC patients. In the past, we have documented pathogenic mutations in BARD1, a BRCA1 interacting protein, in families at high risk for BC. In this study, we have analyzed germline DNA from 61...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Germ-Line Mutation

Share to Homologous Recombination

Share to Triple Negative Breast Neoplasms

Share to Tumor Suppressor Proteins

Share to Ubiquitin-Protein Ligases

Source

Identifiers

PMID: 26010302
DOI: 10.1111/cge.12620

Genes

BARD1
BRCA1
BRCA2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Frequent incidence of BARD1-truncating mutations in germline DNA from triple-negative breast cancer patients.PMID 26010302Read ↗

BARD1 Pathogenic Variants are Associated with Triple-Negative Breast Cancer in a Spanish Hereditary Breast and Ovarian Cancer Cohort.Semantic proximity Read ↗

Multimodal analysis of rare BARD1 missense variant suggests its pathogenicity is conditionalSemantic proximity Read ↗

Functional consequences of a rare missense BARD1 c.403G>A germline mutation identified in a triple-negative breast cancer patient.Semantic proximity Read ↗

Summary of BARD1 Mutations and Precise Estimation of Breast and Ovarian Cancer Risks Associated with the Mutations.Semantic proximity Read ↗

Cancer predisposing BARD1 mutations in breast-ovarian cancer families.Semantic proximity Read ↗

BARD1 mystery: tumor suppressors are cancer susceptibility genesSemantic proximity Read ↗

Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers.Semantic proximity Read ↗

Cancer predisposing missense and protein truncating BARD1 mutations in non-BRCA1 or BRCA2 breast cancer families.Semantic proximity Read ↗

Contribution of BARD1 gene to male breast cancer- report of a family with different types of cancer.Semantic proximity Read ↗

BARD1 homozygous deletion, a possible alternative to BRCA1 mutation in basal breast cancer.Semantic proximity Read ↗

Literature Review of BARD1 as a Cancer Predisposing Gene with a Focus on Breast and Ovarian Cancers.Semantic proximity Read ↗

Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.